U.S. Infrastructure Stock News

If you are wondering whether FTAI Aviation's share price still offers value or if most of the opportunity is already priced in, this article is for you. The stock last closed at US$305.80, with returns of 5.5% over 7 days, 10.9% over 30 days, 45.4% year to date and 139.9% over 1 year, while the 3 year and 5 year returns are both very large. Recent attention on FTAI Aviation has focused on its sharp share price performance and the business model that supports aircraft and engine related...

Steven Madden (NasdaqGS:SHOO) reported Q4 2025 results that came in above its prior guidance. The quarter featured strong performance in its core footwear business and the recently acquired Kurt Geiger brand. The company recorded an impairment on intangible assets related to its portfolio. Management cited ongoing U.S. tariff policy challenges and chose not to issue earnings guidance for 2026. Steven Madden, a well known name in branded footwear and accessories, sits at the intersection of...

If you are wondering whether Bentley Systems' current share price lines up with its underlying worth, this article will walk through what the numbers say and where valuation questions remain open. The stock last closed at US$36.56, with returns of 8.0% over the past 7 days, a 2.1% decline over 30 days, a 4.2% decline year to date, and a 16.2% decline over the past year, along with a 12.7% decline over 3 years and a 20.9% decline over 5 years. Recent coverage of Bentley Systems has focused on...

Great Point Partners has increased its exposure to Apogee Therapeutics (APGE), with filings showing the fund now holds about 9.15% of its assets in the company, alongside advancing atopic dermatitis and asthma programs. See our latest analysis for Apogee Therapeutics. Apogee’s latest US$70.05 share price comes after a mixed few months, with a slightly negative 90 day share price return but a very strong 1 year total shareholder return of about 123%, as investors focus on upcoming trial...

If you are wondering whether Compass at around US$9.84 is priced fairly or offering value, you are not alone. This article is built to help you make sense of that question. The share price has seen a 24.6% decline over the last 30 days, even though the 1 year return sits at 9.4% and the 3 year return is very large. Recent coverage has focused on Compass as a real estate platform operator, with investors watching how its model responds to shifts in housing activity and transaction volumes...

Main Street Capital (MAIN) has wrapped up FY 2025 with fourth quarter revenue of US$145.5 million and EPS of US$1.46. Trailing 12 month figures sit at US$566.4 million of revenue and EPS of US$5.52, setting a clear baseline for how the business is currently earning its keep. The company has seen quarterly revenue range from US$137.0 million to US$145.5 million through 2025, with EPS moving between US$1.31 and US$1.46, and trailing 12 month net income holding in the US$493.4 million area. This...

Crescent Biopharma (CBIO) closed out FY 2025 with Q4 revenue of US$10.8 million, basic EPS of a US$3.35 loss, and a net loss of US$92.4 million. Its trailing twelve month revenue was US$10.8 million, with basic EPS of a US$5.59 loss and a total net loss of US$153.9 million. The company’s quarterly revenue moved from US$0 in the first three quarters of FY 2025 to US$10.8 million in Q4. Over the same period, quarterly basic EPS moved from a US$18.39 loss in Q1 to a US$4.93 loss in Q2, a US$1.27...

In February 2026, Madison Square Garden Sports Corp. announced that Chief Financial Officer, Executive Vice President and Treasurer Victoria Mink will depart after assisting with a potential spin-off and leadership transition. The board is exploring separating the New York Knicks and New York Rangers into two standalone public companies, a move that could reshape how investors assess each franchise’s assets, risks and opportunities. Now we’ll examine how the potential Knicks–Rangers spin-off...

If you are looking at Federal Signal and wondering whether the recent share price puts it at a fair level or not, this article walks through what the current market price might be implying about value. The stock last closed at US$116.43, with a 1.9% decline over the past 7 days, a 6.8% gain over 30 days, a 4.5% return year to date, 44.1% over 1 year, 110.5% over 3 years, and 225.3% over 5 years. Recent news around Federal Signal has largely focused on its position in specialized vehicles and...

Ulta Beauty, NasdaqGS:ULTA, is advancing a global expansion plan under new CEO Kecia Steelman. The company is widening support for women and BIPOC owned brands through its MUSE Accelerator program. Ulta is rolling out AI driven personalization tools to refine customer engagement and product discovery. Ulta Beauty enters this phase of change with its shares at $684.79 and multi year returns that some investors may find meaningful, including 105.4% over 5 years and 86.9% over 1 year. Over...

Galaxy Digital overview Galaxy Digital (GLXY) has been drawing attention after recent share price moves, with returns over the past month and the past 3 months turning negative even as its 1 year total return remains positive. See our latest analysis for Galaxy Digital. The recent 35.45% 1 month share price decline and 22.56% 3 month share price decline contrasts with Galaxy Digital’s very large 3 year total shareholder return. This suggests momentum has cooled even as longer term holders...

Arcosa (ACA) books higher FY 2025 earnings with wider margins Arcosa (ACA) has capped FY 2025 with fourth quarter revenue of US$716.7 million and basic EPS of US$1.06, rounding out a year where trailing twelve month EPS reached US$4.26 on revenue of US$2.88 billion and net income of US$208.4 million. The company reported a current net margin of 7.2% compared with 3.6% a year earlier. Over recent quarters the company has seen revenue move from US$632 million in Q1 2025 to US$716.7 million in...

MGP Ingredients, Inc. has reported past fourth-quarter 2025 results showing sales of US$138.32 million and a net loss of US$134.63 million, driven largely by a very large US$152.62 million goodwill and intangible asset impairment in its Branded Spirits segment. For 2025 as a whole, the company moved from net income to a net loss, while simultaneously closing a US$117.17 million common stock shelf registration, maintaining a quarterly dividend of US$0.12 per share, and issuing 2026 sales...

If you are wondering whether Molson Coors Beverage is fairly priced or offering value right now, you are not alone. This article will walk you through what the numbers are actually saying. The stock closed at US$48.99, with returns of 1.7% decline over the past 7 days, 2.6% over 30 days, 3.4% year to date, 17.7% decline over 1 year, 0.0% over 3 years, and 21.9% over 5 years, which gives a mixed picture of how the market has recently treated the shares. Recent news around the company has...

Progyny (PGNY) has just posted its FY 2025 numbers, with fourth quarter revenue of US$318.4 million and basic EPS of US$0.15, alongside trailing twelve month revenue of about US$1.3 billion and basic EPS of US$0.68. Over the past few quarters, revenue has ranged from US$313.3 million to US$332.9 million with basic EPS moving between US$0.15 and US$0.20, while trailing net income excluding extra items sits at US$58.5 million across the last year. For investors, the headline story focuses on...

If you are looking at AtriCure and wondering whether the current share price reflects its true worth, you are not alone. Many investors are asking the same question right now. The stock recently closed at US$31.25, with returns of a 4.1% decline over 7 days, a 17.3% decline over 30 days and a 20.4% decline year to date, adding to a 19.3% decline over 1 year, a 21.7% decline over 3 years and a 51.0% decline over 5 years. These moves have put more attention on how AtriCure is being valued,...

Covista (CVSA) stock is back in focus after the company used its Investor Day to relaunch under a new name, outline its Purpose at Scale plan, and reaffirm multi year revenue guidance through 2029. See our latest analysis for Covista. Despite the Investor Day updates and long term guidance, Covista’s recent 30 day share price return of a 15.39% decline has taken some heat out of the stock, even as its 3 year total shareholder return of 149.06% and 5 year total shareholder return of 152.78%...

Ramaco Resources reported fourth-quarter 2025 sales of US$128.01 million and a net loss of US$14.71 million, alongside a full-year 2025 net loss of US$51.45 million on sales of US$536.62 million, while also being served with a putative securities class action tied to disclosures about its Brook Mine rare earth project. At the same time, the company outlined progress at Brook Mine and highlighted stronger liquidity following recent financings, underlining how its rare earth ambitions and...

Agilysys (NasdaqGS:AGYS) has been selected by luxury resort Rudding Park to deliver a unified hospitality management platform. The multi year agreement will see Agilysys technology replace fragmented systems across the resort's guest and back office operations. The deal expands Agilysys's presence in high end hospitality, using Rudding Park as a live reference site for its end to end software suite. For investors watching Agilysys, the Rudding Park win lands at a time when the shares trade...

Manchester United (NYSE:MANU) has dismissed manager Ruben Amorim after a brief and costly tenure. Michael Carrick has been appointed interim manager, with early shifts in team performance under his leadership. The club reports a profitability turnaround driven by cost cutting, following recent financial challenges. Manchester United, listed on the NYSE under ticker MANU, is both a football club and a global sports and entertainment brand. The club operates across matchday, media, and...

Chemed (CHE) is back in focus after its fourth quarter and full year 2025 results came in below analyst expectations, with softer margins, cautious 2026 guidance, and operational pressure at both VITAS and Roto Rooter. See our latest analysis for Chemed. That earnings miss and softer 2026 guidance appear to be weighing on sentiment, with a 7 day share price return of 13.72% and a year long total shareholder return of 31.39% pointing to fading momentum despite the buyback activity. If Chemed's...

Recent performance and context for APi Group APi Group (APG) has been drawing attention after a period of mixed short term moves and stronger longer term returns, prompting investors to reassess how its safety and specialty services business is currently priced. See our latest analysis for APi Group. With the share price at US$44.46 after a 6.1% 1 month share price return and a 14.1% year to date share price return, the much stronger 69.8% 1 year total shareholder return suggests momentum has...

In late February 2026, Novavax reported Q4 2025 revenue of US$147.14 million and net income of US$17.53 million, marking a move from loss-making to profitable operations for both the quarter and full year. This earnings swing was heavily supported by partnership-driven milestone payments and improved cost efficiency, underscoring how its collaboration-led model is now a central driver of profitability. Next, we’ll examine how this partnership-fueled return to profitability reshapes...

In the past week, an investigation on behalf of long-term Marex Group plc (NASDAQ: MRX) investors was announced, alleging multi-year accounting schemes involving off-balance-sheet entities, fictitious transactions, and misleading disclosures that may have rendered the company’s financial statements inconsistent and unreliable. The complaint’s focus on potential breaches of fiduciary duties and the integrity of Marex’s reported profits raises direct questions about the quality and...